Loading...
•
Mar 31, 2022
Theravance Q1 2022 Earnings Report
Theravance Biopharma reported financial results for the first quarter of 2022 and provided a business update.
Key Takeaways
Theravance Biopharma reported their Q1 2022 financial results, highlighting their execution against the business plan and remaining on track to become sustainably cash-flow positive by the second half of 2022. YUPELRI's hospital sales performance and market share gains were noted. The company plans to define a path forward for ampreloxetine through discussions with regulators and strategic partners.
Company continues to execute against business plan.
Company remains disciplined in capital allocation.
Company is on track to become sustainably cash-flow positive by the second half of 2022.
Company plans to unlock value from pipeline throughout 2022.
Theravance
Theravance
Forward Guidance
Theravance Biopharma expects to become sustainably cash-flow positive by the second half of this year and going forward on an annual basis.